Quantum BioPharma Ltd
CNSX:QNTM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quantum BioPharma Ltd
Depreciation & Amortization
Quantum BioPharma Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Q
|
Quantum BioPharma Ltd
CNSX:QNTM
|
Depreciation & Amortization
$545.8k
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Depreciation & Amortization
$1.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Depreciation & Amortization
CA$39.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
35%
|
|
|
Cronos Group Inc
TSX:CRON
|
Depreciation & Amortization
$14.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
66%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Depreciation & Amortization
CA$56.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
85%
|
|
Quantum BioPharma Ltd
Glance View
Quantum BioPharma Ltd is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-05-29. Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
See Also
What is Quantum BioPharma Ltd's Depreciation & Amortization?
Depreciation & Amortization
545.8k
USD
Based on the financial report for Dec 31, 2025, Quantum BioPharma Ltd's Depreciation & Amortization amounts to 545.8k USD.
What is Quantum BioPharma Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-33%
Over the last year, the Depreciation & Amortization growth was 11%. The average annual Depreciation & Amortization growth rates for Quantum BioPharma Ltd have been -51% over the past three years , -33% over the past five years .
